Prevention of chemotherapy-induced peripheral neuropathy with classical massage in breast cancer patients receiving paclitaxel: An assessor-blinded randomized controlled trial

Eur J Oncol Nurs. 2019 Jun:40:36-43. doi: 10.1016/j.ejon.2019.03.002. Epub 2019 Mar 22.

Abstract

Purpose: This assessor-blinded, prospective, randomized controlled clinical trial aimed at investigating the effect of classical massage on chemotherapy induced peripheral neuropathy and the quality of life (QOL) in breast cancer patients receiving adjuvant paclitaxel.

Methods: A total of 40 female breast cancer patients were randomly allocated to the classical massage group (CMG) or the control group (CG). Classical massage was applied to the patients in the CMG before each paclitaxel infusion. The CG received only usual care. Presence of peripheral neuropathic pain and QOL were assessed at baseline and weeks 4, 8, 12, and 16. Nerve conduction studies (NCS) findings were also recorded at baseline and week 12.

Results: The peripheral neuropathic pain was lower in the CMG compared to the CG at week 12 (p < 0.05). The sensory and motor sub-scale scores of the QOL measure showed statistically significant differences over time in favor of the CMG (p < 0.05). Sensory action potential amplitude of the median nerve was significantly higher and the tibial nerve latency was significantly shorter in the CMG compared to the CG at week 12.

Conclusions: This study suggested that classical massage successfully prevented chemotherapy-induced peripheral neuropathic pain, improved the QOL, and showed beneficial effects on the NCS findings.

Keywords: Breast cancer; Chemotherapy-induced peripheral neuropathy; Massage therapy; Nerve conduction studies; Nursing; Quality of life.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Antineoplastic Agents / adverse effects*
  • Breast Neoplasms / drug therapy*
  • Female
  • Follow-Up Studies
  • Humans
  • Massage*
  • Middle Aged
  • Neuralgia / chemically induced*
  • Neuralgia / prevention & control*
  • Paclitaxel / adverse effects*
  • Prospective Studies
  • Quality of Life
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Paclitaxel